

ORIGINAL ARTICLE

Achievement of therapeutic targets in Mexican patients with diabetes mellitus

Fernando J. Lavallo-González^{a,*}, Erwin Chiquete^b, Julieta de la Luz^c,
Ana Ochoa-Guzmán^b, Laura V. Sánchez-Orozco^d, Sergio A. Godínez-gutiérrez^e,
the IDMPS-3W collaborative group (Mexico)[◇]

^a Department of Endocrinology, Hospital Universitario "Dr. José Eleuterio González", Monterrey, NL, Mexico

^b Instituto Nacional de Ciencias Médicas y de la Nutrición "Salvador Zubirán", Mexico

^c Medical Research Area, Sanofi-Aventis, Mexico City, Mexico

^d Department of Molecular Biology and Genomics, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Mexico

^e Division of Internal Medicine, Department of Endocrinology, Hospital Civil de Guadalajara "Fray Antonio Alcalde", Guadalajara, Mexico

Received 7 September 2011; accepted 3 July 2012
Available online 6 November 2012

KEYWORDS

Complications;
Diabetes mellitus;
Glycated hemoglobin;
International
Diabetes Management
Practices Study;
Insulin;
Macrovascular;
Microvascular;
Self-monitoring;
Treat-to-target

Abstract

Background and aim: Complications of diabetes comprise the leading cause of death in Mexico. We aimed to describe the characteristics of management and achievement of therapeutic targets in Mexican patients with diabetes mellitus.

Methods: We analyzed data from 2642 Mexican patients with type 1 (T1D, $n = 203$, 7.7%) and type 2 diabetes (T2D, $n = 2439$, 92.3%) included in the third wave of the International Diabetes Management Practices Study.

Results: Of T2D patients, 63% were on oral glucose-lowering drugs (OGLD) exclusively (mostly metformin), 11% on insulin, 22% on OGLD plus insulin, and 4% on diet and exercise exclusively. T2D patients on insulin were more likely to be trained on diabetes, but they were older, had worse control, longer disease duration and more chronic complications than patients on OGLD only. Glycated hemoglobin (HbA1c) $< 7\%$ was achieved by 21% and 37% of T1D and T2D patients, respectively. Only 5% of T1D and 3% of T2D attained the composite target of HbA1c $< 7\%$, blood pressure $< 130/80$ mmHg and low-density lipoprotein cholesterol < 100 mg/dl. T1D patients had less macrovascular but more microvascular complications, compared with T2D patients. Late complications increased with disease duration, so that about 80% of patients after 20 years of diagnosis have at least one late complication. Reaching the target HbA1c $< 7\%$ was associated with a reduced number of microvascular but not with less macrovascular complications.

* Corresponding author.

E-mail address: fjlaallegzz@hotmail.com (F.J. Lavallo-González).

◇ See Appendix A.

PALABRAS CLAVE

Complicaciones;
Diabetes;
Hemoglobina
glucosilada;
International
Diabetes Management
Practices Study;
Insulina;
Macrovascular;
Microvascular;
Autocontrol

Conclusion: A great proportion of these Mexican patients with diabetes did not reach therapeutic targets. Insulin was used mostly in complicated cases with advanced disease.

© 2011 SEEN. Published by Elsevier España, S.L. All rights reserved.

Consecución de los objetivos terapéuticos en pacientes mexicanos con diabetes mellitus

Resumen

Antecedentes y objetivo: Las complicaciones de la diabetes suponen la primera causa de muerte en México. Nuestro propósito fue describir las características del tratamiento y el alcance de objetivos terapéuticos en mexicanos con diabetes mellitus.

Métodos: Analizamos datos de 2.642 mexicanos con diabetes mellitus tipo 1 (DT1, n=203; 7,7%) y tipo 2 (DT2, n=2.439; 92,3%), quienes fueron incluidos en la tercera fase del registro *International Diabetes Management Practices Study*.

Resultados: De los pacientes con DT2, el 65% recibían tratamiento con hipoglucemiantes orales (HO) exclusivamente (principalmente metformina), el 11% insulina, el 22% HO más insulina, y el 4% dieta y ejercicio exclusivamente. Los pacientes con DT2 tratados con insulina habían recibido más educación en diabetes, pero eran más añosos, con peor control, mayor duración de la enfermedad y más complicaciones crónicas que los pacientes tratados con HO solamente. Una hemoglobina glucosilada (HbA1c) < 7% fue alcanzada por el 21 y el 37% de los pacientes con DT1 y DT2, respectivamente. Solo el 5% de los pacientes con DT1 y el 3% con DT2 alcanzaron el objetivo compuesto de una HbA1c < 7%, una presión arterial < 130/80 mmHg y colesterol ligado a lipoproteínas de baja densidad < 100 mg/dl. Los pacientes con DT1 tenían menos complicaciones macrovasculares, pero más microvasculares en comparación con pacientes con DT2. Las complicaciones crónicas aumentaron con la duración de la enfermedad, de tal manera que cerca del 80% de los pacientes después de 20 años de diagnóstico tenían al menos una complicación crónica. El objetivo de HbA1c < 7% se asoció a una frecuencia menor de complicaciones microvasculares, pero no con menos macrovasculares.

Conclusiones: Una gran proporción de estos pacientes mexicanos con diabetes no alcanzaron los objetivos terapéuticos. El tratamiento con insulina se empleó principalmente en casos complicados con enfermedad avanzada.

© 2011 SEEN. Publicado por Elsevier España, S.L. Todos los derechos reservados.

Introduction

Diabetes mellitus is a growing health and social problem worldwide, especially in low-income countries, where the economical and cultural transition toward a lifestyle of excessive energy intake and low energy expenditure is taking place.¹⁻⁷ The prevalence of diabetes mellitus in Mexican adults is 14.4%, with about 50% new cases diagnosed during population screening.⁸ This frequency is higher than that of the total Latin American population.⁶

Optimized care reduces acute and long-term complications, while improving quality of life⁹⁻¹⁷; but despite evidence-based guidelines, it is precisely in developing countries where diabetes is diagnosed late and standards of care are not completely followed as recommended.¹⁻⁶ There is scarce information about contemporary clinical care delivered to patients with diabetes in developing countries,^{1,2} which may represent a barrier in designing co-founded efforts aimed to improve the way these nations deal with diabetes burden.⁵ The International Diabetes Management Practices Study (IDMPS) is an ongoing 5-year survey designed to provide information regarding clinical practice and care delivered to patients with type 1 (T1D) and type 2 diabetes mellitus (T2D) in developing countries.^{1,2} The main objective is to document changes in

clinical practice over a 5-year period, starting in November 2005, and organizing recruitment in 5 waves (every 12 months each). The aim of the present report is to describe the characteristics of the medical care delivered to Mexican patients with diabetes mellitus included in the 2007 registry (3rd wave) of IDMPS. We also describe the prevalence of micro and macrovascular complications, according to the type of treatment.

Methods

Study design

IDMPS is an international, multicenter, prospective, observational study on patients with T1D and T2D. The design of this survey is in accordance to STROBE guidelines, as described elsewhere.^{1,2} Briefly, IDMPS is composed of 5 cross-sectional registries (operationally called "waves") in a 5-year period to assess changing practices in the management of subjects with diabetes mellitus. Each wave consists of two phases: a 2-week cross-sectional registry and a 9-month longitudinal survey. A 3-month interval separates the end of the longitudinal survey and the start of the next wave. Only data on the cross-sectional registry are analyzed in the present report.

The number of subjects to be recruited in each participating country is determined on a country basis. Based on the assumption that insulin is the least prescribed therapy, the sample is determined in order to establish the frequency of insulin-treated patients.^{1,2} Physicians were invited to participate with a maximum of 10 patients with T2D and 5 with T1D. A total of 200 Mexican physicians participated in the 2007 wave. Physicians were invited to participate if they had experience using insulin and treating both T1D and T2D patients. From five to eight physicians pertaining to each of the 31 Mexican States were invited to participate, depending on the population density, but stratification of the States population was not performed to calculate sample size. The internal Committee of Ethics of each participating center reviewed and approved patient enrollment.

Participation criteria

Male and female patients ≥ 18 years of age diagnosed with either T1D or T2D, visiting the physician during the recruitment period of the cross sectional phase, could be selected to enter the study. Patient selection was not randomly assigned. Written informed consent was required for all patients. Patients were excluded if they had concomitant participation in another clinical descriptive or interventional study, if they participated in a previous wave of IDMPS, or if they were under temporary insulin treatment (gestational diabetes, surgery, pancreas cancer, sepsis and other conditions).

Data collection

Information was collected on standardized electronic and hard case report forms (CRFs) about demographics, medical history, pharmacologic and lifestyle therapy, glycemic control (fasting glucose and glycosylated hemoglobin (HbA1c)) and other therapeutic targets such as blood pressure, low density lipoprotein cholesterol (LDL-C), albuminuria, blood glucose self-monitoring, access to diabetes education, access to specialized care, hospitalizations, medical complications (i.e., diabetic neuropathy, cataracts, retinopathy, renal insufficiency, heart failure, myocardial infarction, stroke, peripheral artery disease and diabetic foot ulcer) and work absenteeism, among other variables. The participating physicians filled data in the paper CRF. The filled CRF was sent to the Sanofi-Aventis data management affiliate that reviewed every CRF for consistency and completeness. Every CRF was registered in a web-based data capture system. Any conflicting information and query was returned to the participating physician for clarification. Blood pressure measurements and laboratory analyses registered were those practiced locally by each participating physician with standard procedures. No central laboratory testing was utilized. Blood pressure was measured in the physician's office with a sphygmomanometer with participants seated after 5 min of rest, in the right arm at the heart level. Blood pressure (BP) was measured twice, each 5 min apart. A third measurement was made if the blood pressures differed by more than 10 mmHg in systolic and 5 mmHg in diastolic readings. Diabetes-related complications were documented by a competing specialist,

depending on the particular complication (an ophthalmologist for eye complications, a cardiologist for coronary heart disease, a neurologist for cerebrovascular disease and diabetic neuropathy, and a vascular surgeon for peripheral artery disease). These specialists were invited at the discretion of the IDMPS participating physician for the evaluation of possible diabetes-related complications exclusively.

Statistical analysis

Parametric continuous variables are expressed as geometric means and standard deviations (SD), or minimum and maximum. Categorical variables are expressed as percentages. Student's *t* test was performed to compare quantitative variables parametrically distributed between two groups. Chi-square statistics were used to compare nominal variables in univariate analyses. All *p* values are two-sided and regarded as significant when $p < 0.05$. Statistical analyses were conducted with the SAS Software version 8.02.

Results

In Mexico, 3052 patients with diabetes were recruited in 2007 (IDMPS 3rd wave) by 200 physicians: 58 endocrinologists/diabetologists, and 57 primary care practitioners/internists/cardiologists. A total of 2642 (87%) patients met the eligibility criteria: 203 T1D (60.6% women, mean age 31.26, range 18–71; 76.8% aged < 40 years) and 2439 T2D patients (60.2% women, mean age 56.7, range 18–95; 9.3% aged < 40 years) (Table 1). A total of 91% of T1D and 89% of T2D patients pertained to urban areas. The characteristics of drug therapy are shown in Table 2.

T2D patients under insulin treatment were more frequently trained on diabetes than patients on OGLD alone, and more frequently trained than patients managed with diet and exercise only (Table 3). Moreover, T1D patients were more likely to have formal education on diabetes than did T2D patients ($p < 0.05$). T1D patients had a mean (SD) of 6 (3.5) laboratory testings for fasting blood glucose (FBG), while T2D patients had a mean (SD) of 5.5 (7.5) measurements. Among T1D patients, 84% had a personal glucometer at home as compared with 56.9% of T2D patients ($p < 0.001$). T2D patients treated with diet and exercise exclusively had the lower rate of self-monitoring. Only 20.9% of T1D patients and 36.8% of T2D patients had attained the target value of HbA1c < 7% at the time of the registry (Table 3). Only 4% of the whole population had attained the 3-goal target of HbA1c < 7% plus BP < 130/80 mmHg plus LDL-C < 100 mg/dl (2.7% in T2D and 5.3% in T1D patients, $p < 0.001$).

Any late diabetes-related complication was registered for 39.1% of T1D patients and 45.2% of T2D cases ($p = 0.01$). Among T1D patients with ≥ 1 late complication, 98.7% had at least one microvascular and 13.9% at least one macrovascular complication. In contrast, among T2D patients who had at least one late complication, 88.8% had at least one microvascular and 41.5% at least one macrovascular complication (Table 4). There was a direct relationship between the number of late complications and time since diagnosis of diabetes (Fig. 1). In T1D patients, no significant differences were observed in the prevalence of micro or macrovascular complications grouped or analyzed

Table 1 General characteristics of type 1 and type 2 diabetic patients included in the IDMPS 3rd wave ($n=2642$) according to type of treatment.^a

Variable	T1D patients ($n=203$)	T2D patients				
		OGLD treatment alone ($n=1537$)	Insulin treatment alone ($n=266$)	OGLD + insulin ($n=544$)	Diet and exercise only ($n=92$)	Total T2D patients ($n=2439$)
Age (years), mean (range)	31.3 (18–71)	56.5 (19–95)	58.9 (21–94)	56.8 (18–92)	54.1 (29–82)	56.7 (18–95)
Female, n (%)	120 (60.6)	898 (61.0)	152 (60.8)	316 (59.3)	45 (50.0)	1411 (60.2)
BMI, mean ^b	24.6 (4.3)	29.8 (5.7)	28.6 (5.5)	29.5 (5.9)	28.9 (6.1)	29.6 (5.8)
Waist circumference, mean ^b	83.8 (11.9)	99.0 (13.6)	97.3 (13.6)	98.8 (13.5)	99.3 (15.1)	98.8 (13.6)
Time since diagnosis (years), mean (range)	12.1 (9.7)	7.4 (6.8)	14.3 (8.7)	13.3 (8.4)	5.1 (7.3)	9.4 (8.0)
Any diabetes-related complication, n (%)	79 (39.1)	567 (37.0)	175 (66.0)	330 (60.7)	29 (31.5)	1101 (45.2)
SBP, mean ^b	114.9 (18.2)	126.2 (16.6)	129.1 (19.7)	127.1 (18.4)	126.1 (18.4)	126.8 (17.5)
DBP, mean ^b	73.6 (10.0)	77.9 (9.5)	77.8 (9.8)	76.7 (9.5)	77.1 (10.7)	77.6 (9.6)
SBP ≥ 130 and/or DBP ≥ 80 mmHg, n (%)	81 (41.3)	1016 (68.6)	184 (70.8)	338 (63.7)	52 (59.1)	1590 (67.3)
History of hypertension, n (%)	47 (23.2)	814 (53.2)	157 (59.2)	320 (58.9)	38 (43.2)	1329 (54.8)
Current smoking status, n (%)	16 (7.9)	103 (6.7)	12 (4.5)	40 (7.4)	6 (6.5)	161 (6.6)
Antiplatelet therapy, n (%)	36 (18.4)	552 (36.8)	114 (44.5)	224 (42.1)	16 (18.4)	906 (38.2)
<i>Professional who made the diagnosis of diabetes</i>						
Diabetologist/endocrinologist, n (%)	72 (36.9)	304 (20.3)	45 (17.6)	76 (14.3)	21 (23.6)	446 (18.8)
Primary care practitioner/internist/cardiologist, n (%)	123 (63.0)	1197 (79.7)	211 (82.5)	454 (85.6)	68 (76.4)	1930 (81.2)

BMI, body mass index; DBP, diastolic blood pressure; OGLD, oral glucose lowering drugs; SBP, systolic blood pressure; T1D, type 1 diabetes mellitus; T2D, type 2 diabetes mellitus.

^a Figure numbers may not sum up the “ n ” for each column, due to missing information of individual patients.

^b Means with standard deviations in parentheses.

Table 2 Drug therapy of type 1 and type 2 diabetic patients included in the IDMPs 3rd wave ($n = 2642$).^a

Variable	T1D patients	T2D patients			
		OGLD treatment alone	Insulin treatment alone	OGLD + insulin	Total T2D patients
<i>Class of OGLD treatment</i>					
Metformin, n (%)	15 (38.5)	307 (20.6)	0 (0)	138 (26.8)	445 (22.2)
Sulphonylureas, n (%)	3 (7.7)	151 (10.2)	0 (0)	42 (8.2)	193 (9.6)
Metformin + sulphonylureas, n (%)	7 (17.9)	673 (45.3)	0 (0)	212 (41.2)	885 (44.2)
Other, n (%)	14 (35.9)	356 (23.9)	0 (0)	122 (23.7)	478 (23.9)
<i>Current insulin treatment</i>					
Basal alone, n (%)	56 (28.0)	0 (0)	173 (65.3)	386 (71.0)	559 (69.1)
Basal + prandial, n (%)	120 (60.0)	0 (0)	35 (13.2)	61 (11.2)	96 (11.9)
Others, n (%)	15 (38.5)	0 (0)	0 (0)	138 (26.8)	445 (22.2)
Prandial alone, n (%)	3 (1.5)	0 (0)	9 (3.4)	10 (1.8)	19 (2.3)
Premix alone, n (%)	15 (7.5)	0 (0)	43 (16.2)	80 (14.7)	123 (15.2)

NPH, neutral protamine Hagedorn; OGLD, oral glucose lowering drugs; T1D, type 1 diabetes mellitus; T2D, type 2 diabetes mellitus.

^a Figure numbers may not sum up the "n" for each column, due to missing information of individual patients.

separately with respect to a target HbA1c (all late complications: 26.5% vs. 43.4%, for patients with HbA1c < 7% or \geq 7%, respectively; $p = 0.17$). On the other hand, in T2D patients, both micro and macrovascular complications were more frequent among patients not reaching the HbA1c target, than in those attaining this goal (all complications: 49.4% vs. 34.0%, for patients with HbA1c < 7% or \geq 7%,

respectively; $p < 0.001$). Furthermore, microvascular complications were significantly less frequent in T2D patients achieving the HbA1c target than those uncontrolled (84.9% vs. 91.2%, for patients with HbA1c < 7% or \geq 7%, respectively; $p = 0.02$); however, the number of macrovascular complications did not differ between patients reaching or not reaching the target of HbA1c < 7% (37.4% vs.

Table 3 Patients' education on diabetes, screening for complications and achievement of therapeutic goals according to the type of diabetes mellitus.^a

Variable	T1D patients	T2D patients
Membership in a diabetes patients association, n (%)	24 (12.5)	84 (3.7)
Training in diabetes, n (%)	132 (65.3)	1135 (47.8)
<i>Type of training</i>		
Individual, n (%)	76 (58.9)	784 (69.7)
Group, n (%)	30 (23.3)	251 (22.3)
Last laboratory FBG value, mean ^b	177.1 (79.2)	173.6 (80.3)
<i>Patients practicing blood glucose self-monitoring</i>		
Preprandial (FBG), n (%)	161 (80.5)	1341 (56.0)
Postprandial, n (%)	161 (80.5)	1326 (55.2)
>30 times per month, n (%)	115 (57.8)	621 (26.1)
	37 (23.7)	37 (2.9)
Frequency of HbA1c tests during the last year, mean ^b	2.7 (1.4)	2.1 (1.4)
Value of last HbA1c measurement, mean ^b	8.8 (2.3)	8.0 (2.1)
Months since the last HbA1c measurement, mean ^b	2.3 (3.4)	3.0 (6.2)
HbA1c < 7%, n (%)	34 (20.9)	526 (36.8)
HbA1c > 9%, n (%)	57 (35.0)	358 (25.1)
<i>Patients with HbA1c < 7% by physician's specialty</i>		
Diabetologists/Endocrinologists, n (%)	14 (16.9)	205 (38.4)
Primary Care practitioners/Internists/Cardiologists, n (%)	9 (36.0)	97 (34.6)
Composite target HbA1c < 7%/BP < 130/80 mmHg/LDL-C < 100 mg/dl, n (%)	9 (5.3)	57 (2.7)

BP, blood pressure; FBG, fasting blood glucose; HbA1c, glycosylated hemoglobin A1c; LDL-C, low-density lipoprotein cholesterol; T1D, type 1 diabetes mellitus; T2D, type 2 diabetes mellitus.

^a Figure numbers may not sum up the "n" for each column, due to missing information of individual patients.

^b Means with standard deviations in parentheses.

Table 4 Late complications in type 1 and type 2 diabetic patients ($n=2527$).

Variable	T1D patients	T2D patients
Any late diabetes-related complication*	39.1%	45.2%
Any microvascular complication	98.7%	88.8%
Retinopathy*	51.9%	42.5%
Nephropathy*	51.9%	37.3%
Neuropathy	63.3%	62.8%
Any macrovascular complication*	13.9%	41.5%
Coronary artery disease*	2.5%	19.6%
Stroke*	0%	2.7%
Peripheral vascular disease*	11.4%	24.5%

T1D, type 1 diabetes mellitus; T2D, type 2 diabetes mellitus.
* $p < 0.05$, for comparison between T1D and T2D patients.




Figure 1 Frequency of any late diabetes-related complication (either micro or macrovascular) for type 1 and type 2 diabetic patients according to time since diagnosis of diabetes mellitus ($n=2642$). T1DM: type 1 diabetes mellitus; T2DM: type 2 diabetes mellitus.

39.3%, for patients with HbA1c $< 7\%$ or $\geq 7\%$, respectively; $p=0.66$).

Discussion

We confirmed previous observations about the wide gap between current standards and care delivered to Mexican patients with diabetes mellitus.^{4,5} Even when IDMPs included mostly physicians familiarized with insulin therapy, in T2D patients this option is still reserved for long-lasting and complicated cases, mainly patients in whom lifestyle modifications and OGLD therapy had failed. And worryingly, a significant proportion of patients with T1D were treated with OGLD in combination with insulin, a strategy not supported in current recommendations. In this study only a minority of patients with diabetes mellitus had the recommended target value of HbA1c $< 7\%$. In contrast, in

high-income nations a transition toward better practice and quality of care delivered to patients with diabetes has been observed in the last years.¹⁸ A USA study on 1334 T1D and T2D patients included in the National Health and Nutrition Examination Survey (NHANES) 1999–2004 documented that in the period 1999–2000 an unadjusted 37% of this population had HbA1c $< 7\%$, increasing to 56.8% in the period 2003–2004.¹⁷ A similar picture is observed in European countries.^{19,20} For example, the 10-year Spanish observational study RedGEDAPS has clearly shown an improvement in patient control and achievement of therapeutic goals with a significant reduction in late complication from 1996 to 2007. In contrast, low-income nations from Latin America, Eastern Europe and Asia have a frequency of patients being at therapeutic goals that is comparable with the figures provided in the present Mexican report.¹ In general, in low-income countries insulin therapy and cardiovascular disease prevention are installed late and management of non-glycemic goals (chiefly lipids and blood pressure) are usually reserved for a “second step” after glycemic control is achieved. Unfortunately, the latter objective is never achieved in many cases.

Current scientific evidence has shown a direct relationship between HbA1c and microvascular complications.¹⁶ However, randomized trials have failed in demonstrating that stringent glycemic control reduces the risk of macrovascular complications.^{13–15} This emphasizes the need for a better management of non-glycemic therapeutic goals. Very similar conclusions have been obtained for the case of tight blood pressure control in two recent studies on patients with diabetes who already have coronary artery disease.^{21,22} Less stringent goals may be appropriate for certain subgroups of patients.²³ That cardiovascular disease is not sufficiently delayed in most patients with diabetes only demonstrates the necessity of action in early stages, before irreversible vascular injuries accrue.^{24–26} This notion is in part supported by the observation that primary prevention of arterial thrombotic disease with antiplatelet therapy (an strategy that prevents thrombosis in an already damaged endothelium) provides no net clinical benefit in diabetic patients without other cardiovascular risk factors.²⁶ Therefore, redoubled efforts are needed to reduce the immense health, social and economical burden that is imposed by diabetes around the world.^{27–30}

The main limitations of this study are the cross-sectional design, the lack of standardized laboratory assays²⁹, lack of standardized assessments of diabetes-related complications and the lack of random selection for both participating physicians and their patients. Nevertheless, this study highlights the need for a more aggressive attitude in delivering of care to patients with diabetes in Mexico. These data provide important basis for immediate institutional actions toward improvement of management of patients with the most important chronic disease in Mexico. There is a need for more studies evaluating international recommendations adequacy in developing countries.²⁸

Conflicts of interest

Julieta de la Luz, MD: employee of Sanofi-Aventis, Medical Area.

Acknowledgements

This registry received unrestricted funds from Sanofi-Aventis. The company designed and partially conducted and monitored the study; nonetheless, the company did not participate in the selection of patients, data capture, data analysis, manuscript draft or the decision to submit for publication.

Appendix A.

The authors are indebted to all IDMP5-3W collaborators in Mexico (in alphabetic order) as follows: Acevedo G., Acosta I., Alpizar M., Altamirano E., Álvarez A., Álvarez P., Anaya C., Arellano S., Arreola M., Arroyo A., Arteaga V., Ascensión D., Baeza B., Bancalari C., Baqueiro J., Barón D., Barragán A., Barrientos M., Bastidas M., Bautista J., Beltrán L., Blanco A., Caballero S., Calarco E., Calderón R., Camacho L., Cano R., Caracas N., Cardoso S., Carrillo P., Carvajal M., Casco S., Castañeda R., Castelán F., Castillo O., Cerda I., Cervantes A., Chávez M., Chávez L., Chavira I., Cilia J., Cisneros H., Colín M., Collado E., Colome J., Conrado S., Correa A., Covarrubias M., Cruz E., Dávila O., De la garza N., Del pozo J., Díaz E., Domínguez C., Encinas E., Escalante A., Escalante J., Escalante M., Escudero I., Espinoza J., Estrada A., Estrada K., Fabián M., Fanghanel G., Farjat J., Fernández A., Flores M., Flores V., Franco M., Franco V., Gallardo V., Gamboa F., Garcia H., Garcia J., Garcia L., Garcia J., García P., Garza R., Gomez V., Gonzalez A., Gonzalez G., Gonzalez I., González A., Granillo M., Grover F., Guajardo M., Guerrero J., Gutierrez M., Guzmán J., Guzmán A., Hall J., Hamilton L., Handall V., Hernandez A., Hernandez F., Hernández A., Hernández J., Herrera L., Herrera M., Hinojos L., Ibáñez M., Ibarra A., Ibarra M., Jiménez M., Jurado M., Lavallo F., Lechuga D., Llanas D., Lopez S., López H., López R., Lozano J., Lucio F., Luna R., Macedo N., Macías A., Magallanes F., Maldonado D., Maldonado J., Mancillas L., Mar F., Marquez E., Martínez A., Martínez R., Martínez R., Matildes M., Mauricio G., Mejía A., Mejía J., Mejía L., Mejía M., Mendoza E., Mendoza P., Mercado F., Meza E., Moctezuma J., Moleres J., Monreal R., Montemayor D., Monterrubio N., Montoya J., Mora F., Morales D., Morales F., Morales M., Moreno F., Moreno L., Moreno M., Muñoz A., Muñoz T., Navallas E., Nevares L., Nevarez L., Niño J., Núñez A., Ochoa A., Olmedo V., Ortega A., Osorio D., Ovando R., Parra F., Pascoe S., Pérez C., Pérez H., Pérez N., Quezada M., Radillo P., Rajme V., Ramírez B., Ramírez J., Ramos L., Ramos M., Ríos E., Rivera E., Robles J., Rodríguez H., Rodríguez J., Rodríguez J., Rodríguez J., Rodríguez H., Rodríguez R., Romero A., Rosado C., Rosas M., Rosiles S., Rubio Y., Ruiz D., Ruiz E., Saavedra E., Salas R., Salazar H., Salinas S., Sanchez B., Sanchez H., Sanchez L., Sanchez R., Sanchez S., Sanchez S., Sanchez B., Sandoval R., Sandoval B., Santibáñez M., Seamanduras L., Secchi N., Solís T., Sosa A., Taméz H., Tapia M., Téllez J., Torres J., Torres E., Torres P., Trasviña K., Trejo M., Triano A., Triano M., Uribe A., Vadillo M., Valdez M., Valdovinos S., Valencia H., Vales M., Valladares Z., Vargas M., Vázquez J., Vázquez J., Vázquez J., Vázquez P., Vidrio M., Villanueva S., Wakida H., Yamamoto J., Zamora A., Zayas F.

References

1. Chan JC, Gagliardino JJ, Baik SH, Chantelot JM, Ferreira SR, Hancu N, et al. Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS). *Diabetes Care*. 2009;32:227–33.
2. Ringborg A, Cropet C, Jönsson B, Gagliardino JJ, Ramachandran A, Lindgren P. Resource use associated with type 2 diabetes in Asia Latin America, the Middle East and Africa: results from the International Diabetes Management Practices Study (IDMPS). *Int J Clin Pract*. 2009;63:997–1007.
3. Villalpando S, Shamah-Levy T, Rojas R, Aguilar-Salinas CA. Trends for type 2 diabetes and other cardiovascular risk factors in Mexico from 1993–2006. *Salud Publica Mex*. 2010;52:572–9.
4. Barquera S, Tovar-Guzmán V, Campos-Nonato I, González-Villalpando C, Rivera-Dommarco J. Geography of diabetes mellitus mortality in Mexico: an epidemiologic transition analysis. *Arch Med Res*. 2003;34:407–14.
5. Sosa-Rubí SG, Galárraga O, López-Ridaura R. Diabetes treatment and control: the effect of public health insurance for the poor in Mexico. *Bull World Health Organ*. 2009;87:512–9.
6. Escobedo J, Buitrón LV, Velasco MF, Ramírez JC, Hernández R, Macchia A, et al. CARMELA Study Investigators High prevalence of diabetes and impaired fasting glucose in urban Latin America: the CARMELA Study. *Diabet Med*. 2009;26:864–71.
7. Fanghanel Salmón G, Sánchez-Reyes L, Chiquete Anaya E, de la Luz Castro J, Escalante Herrera A. Multicenter international registry to evaluate the clinical practice delivered to patients with type 2 diabetes mellitus: a sub-analysis of the experience in Mexico. *Gac Med Mex*. 2011;147:226–33.
8. Villalpando S, de la Cruz V, Rojas R, Shamah-Levy T, Avila MA, Gaona B, et al. Prevalence and distribution of type 2 diabetes mellitus in Mexican adult population: a probabilistic survey. *Salud Publica Mex*. 2010;52:S19–26.
9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes source. *Lancet*. 1998;352:837–53.
10. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes source. *Lancet*. 1998;352:854–65.
11. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. *Diabetes Care*. 2000;23:B2–29.
12. ACCORD Study Group Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. *Am J Cardiol*. 2007;99:21i–33i.
13. Action to Control Cardiovascular Risk in Diabetes Study Group Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med*. 2008;358:2545–59.
14. ADVANCE Collaborative Group Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2008;358:2560–72.
15. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med*. 2009;360:129–39.
16. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. *Diabetes Care*. 2009;32:187–92.

17. American Diabetes Association. Standards of medical care in diabetes—2010. *Diabetes Care*. 2010;33:511–61.
18. Ford ES, Li C, Little RR, Mokdad AH. Trends in A1C concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004. *Diabetes Care*. 2008;31:102–4.
19. Franch Nadal J, Artola Menéndez S, Diez Espino J, Mata Cases M. en representación de la Red de Grupos de Estudio de la Diabetes en Atención Primaria de la Salud Evolución de los indicadores de calidad asistencial al diabético tipo 2 en atención primaria (1996–2007). Programa de mejora continua de calidad de la Red de Grupos de Estudio de la Diabetes en Atención Primaria de la Salud. *Med Clin (Barc)*. 2010;135:600–7.
20. Vaghela P, Ashworth M, Schofield P, Gulliford MC. Population intermediate outcomes of diabetes under pay-for-performance incentives in England from 2004 to 2008. *Diabetes Care*. 2009;32:427–9.
21. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. *JAMA*. 2010;304:61–8.
22. ACCORD Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. *N Engl J Med*. 2010;363:233–44.
23. Miller ME, Bonds DE, Gerstein HC, Seaquist ER, Bergenstal RM, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. *BMJ*. 2010;340:b5444.
24. Comi-Diaz C, Miralles-García JM, Cabrerizo L, Pérez M, Masramon X, De Pablos-Velasco P, Grupo de Investigadores del Estudio Melodía Sociedad Española de Endocrinología y Nutrición. Cardiovascular risk factor control in a population with longstanding diabetes attending endocrinology departments. *Endocrinol Nutr*. 2010;57:472–8.
25. Del Cañizo Gómez FJ, Fernández Pérez C, Moreno Ruiz I, de Gorospe Pérez-Jáuregui C, Silveira Rodríguez B, González Losada T, et al. Microvascular complications and risk factors in patients with type 2 diabetes. *Endocrinol Nutr*. 2011;58:163–8.
26. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. *Circulation*. 2010;121:2694–701.
27. Villarreal-Ríos E, Salinas-Martínez AM, Medina-Jáuregui A, Garza-Elizondo ME, Núñez-Rocha G, Chuy-Díaz ER. The cost of diabetes mellitus and its impact on health spending in Mexico. *Arch Med Res*. 2000;31:511–4.
28. Aguilar-Salinas C, Velazquez MO, Gómez-Perez F, Lara EA, Molina CV, et al. Characteristics of patients with type 2 diabetes in Mexico: results from a large population-based nationwide survey. *Diabetes Care*. 2003;26:2021–6.
29. Gagliardino JJ, Aschner P, Baik SH, Chan J, Chantelot JM, Ilkova H, et al. IDMPs investigators Patients' education, and its impact on care. outcomes, resource consumption and working conditions: data from the International Diabetes Management Practices Study (IDMPS). *Diabetes Metab*. 2012;38:128–34.
30. Costi M, Smith H, Reviriego J, Castell C, Goday A, Dilla T. Direct health care costs in patients with type 2 diabetes mellitus six months after starting insulin treatment in Spain: the INSTIGATE study. *Endocrinol Nutr*. 2011;58:274–82.